Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin pharmacokinetics after adjusted dosing for high BMI, low serum creatinine, and capped renal function
2014-000234-33Phase 4Active
- Sponsor
- Rijnstate
- Start
- May 2014
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of carboplatin in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and ovarian cancer, sponsored by Rijnstate. Primary endpoints: Mean prediction error of carboplatin AUC and Mean absolute prediction error of carboplatin AUC. Started May 2014; status: active.
02
Drugs
carboplatin
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)ovarian cancer
Beyond the preview
Go deeper on 2014-000234-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000234-33.